These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 2433011

  • 41. Antenatal maternal serum profiles.
    Spencer K.
    Br J Hosp Med; ; 51(5):243-6. PubMed ID: 7518729
    [Abstract] [Full Text] [Related]

  • 42. A cost-utility analysis of antenatal screening to prevent congenital rubella syndrome.
    Lugnér AK, Mollema L, Ruijs WL, Hahné SJ.
    Epidemiol Infect; 2010 Aug; 138(8):1172-84. PubMed ID: 20018128
    [Abstract] [Full Text] [Related]

  • 43. Maternal serum alphafetoprotein screening. University Medical Center.
    Morris N, Riconda D, Marfatia L, Ostrer H.
    J Fla Med Assoc; 1991 Jun; 78(6):365-8. PubMed ID: 1714937
    [Abstract] [Full Text] [Related]

  • 44. Antenatal screening in Oxford for fetal neural tube defects.
    Wald NJ, Cuckle HS, Boreham J, Brett R, Stirrat GM, Bennett MJ, Turnbull AC, Solymar M, Jones N, Bobrow M, Evans CJ.
    Br J Obstet Gynaecol; 1979 Feb; 86(2):91-100. PubMed ID: 85462
    [Abstract] [Full Text] [Related]

  • 45. In California, voluntary mass prenatal screening.
    Steinbrook R.
    Hastings Cent Rep; 1986 Oct; 16(5):5-7. PubMed ID: 2429941
    [Abstract] [Full Text] [Related]

  • 46. Can we afford screening for neural tube defects? The South Wales experience.
    Hibbard BM, Roberts CJ, Elder GH, Evans KT, Laurence KM.
    Br Med J (Clin Res Ed); 1985 Jan 26; 290(6464):293-5. PubMed ID: 3917791
    [Abstract] [Full Text] [Related]

  • 47. Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a combined study in Germany and short overview on screening in populations with low birth prevalence of neural tube defects.
    Fuhrmann W, Weitzel HK.
    Hum Genet; 1985 Jan 26; 69(1):47-61. PubMed ID: 2578423
    [Abstract] [Full Text] [Related]

  • 48. Maternal serum alpha-fetoprotein screening for neural tube defects. Report of a program with more than 30000 screened pregnancies.
    Candenas M, Villa R, Fernandez Collar R, Moina MJ, Pintado S, Garcia Saez F, Alvarez FV.
    Acta Obstet Gynecol Scand; 1995 Apr 26; 74(4):266-9. PubMed ID: 7537429
    [Abstract] [Full Text] [Related]

  • 49. Measuring the benefits of screening for open neural tube defects.
    Henderson JB.
    J Epidemiol Community Health; 1982 Sep 26; 36(3):214-9. PubMed ID: 6815296
    [Abstract] [Full Text] [Related]

  • 50. Prevalence of neural tube defects in United States Army treatment facilities, 1975-1985; cost analysis of routine screening.
    Boling RO, Schipul AH, Barnhill DR, Chaney S, Beam TL.
    Mil Med; 1988 Jun 26; 153(6):293-5. PubMed ID: 2455252
    [No Abstract] [Full Text] [Related]

  • 51. Cost-effectiveness analysis of prenatal diagnosis: methodological issues and concerns.
    Caughey AB.
    Gynecol Obstet Invest; 2005 Jun 26; 60(1):11-8. PubMed ID: 15692215
    [Abstract] [Full Text] [Related]

  • 52. The development of action lines in an Australian maternal serum alphafetoprotein screening service for neural tube defects.
    Nicolas T, Nicholls EM, Robertson RD, Bonifacio M, Sinosich M, Field B, Saunders DM.
    Aust N Z J Obstet Gynaecol; 1988 Feb 26; 28(1):12-6. PubMed ID: 2463829
    [Abstract] [Full Text] [Related]

  • 53. Maternal serum alpha-fetoprotein screening for neural tube defects. Results of a consensus meeting.
    Prenat Diagn; 1985 Feb 26; 5(1):77-83. PubMed ID: 2579375
    [No Abstract] [Full Text] [Related]

  • 54. Serum alpha-feto protein screening for neural tube defects: some notes for programme evaluators.
    Mason ES, Clarke M.
    J R Soc Health; 1986 Dec 26; 106(6):210-2. PubMed ID: 2433441
    [No Abstract] [Full Text] [Related]

  • 55. Costs and benefits of serum alpha-fetoprotein screening.
    Read AP.
    Br Med J; 1986 Dec 26; 2(6154):1787. PubMed ID: 83895
    [No Abstract] [Full Text] [Related]

  • 56. ACOG practice bulletin. Neural tube defects. Number 44, July 2003. (Replaces committee opinion number 252, March 2001).
    Cheschier N, ACOG Committee on Practice Bulletins-Obstetrics.
    Int J Gynaecol Obstet; 2003 Oct 26; 83(1):123-33. PubMed ID: 14626221
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. What participants understand about a maternal serum alpha-fetoprotein screening program.
    Faden RR, Chwalow AJ, Orel-Crosby E, Holtzman NA, Chase GA, Leonard CO.
    Am J Public Health; 1985 Dec 26; 75(12):1381-4. PubMed ID: 2415009
    [Abstract] [Full Text] [Related]

  • 59. Influence of provider characteristics and insurance status on maternal serum alpha-fetoprotein screening.
    Jenkins-Woelk LD, Baldwin LM, Raine TR, Hart LG, Fordyce MA, Rosenblatt RA.
    J Am Board Fam Pract; 1998 Dec 26; 11(5):357-65. PubMed ID: 9796765
    [Abstract] [Full Text] [Related]

  • 60. A cost-benefit analysis of a population screening programme for neural tube defects.
    Sadovnick AD, Baird PA.
    Prenat Diagn; 1983 Dec 26; 3(2):117-26. PubMed ID: 6413966
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.